COMMUNIQUÉS West-GlobeNewswire

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
27/04/2026
Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant Disease PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or [...]
Weight Watchers Announces Actions to Utilize Up to $40 million to Pay Down Debt
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it intends to utilize up [...]
Sagimet Biosciences Provides Strategic and Corporate Updates
27/04/2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Further MASH [...]
NIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product Innovation
27/04/2026
Recognition honors the ground-up rebuild of NIMA’s gluten sensor, app, and quality systems BOSTON, April 27, 2026 (GLOBE NEWSWIRE) -- NIMA Partners, Inc . announced today it has been named the winner of a Gold Stevie® [...]
Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group
27/04/2026
Board Determines Proposal Significantly Undervalues Seer and Is Not in the Best Interests of Stockholders REDWOOD CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the [...]
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
27/04/2026
Expect to complete BLA submission in second half of 2026; anticipate launch in first half of 2027, if approved CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading [...]
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
27/04/2026
Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for eligibility for Breakthrough Therapy Designation Vancouver, Canada, April 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine [...]
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
27/04/2026
VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative [...]
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
27/04/2026
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of median progression-free [...]
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
27/04/2026
Patent expected to be formally granted within three months, subject to standard administrative procedures Patent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP [...]
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
27/04/2026
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and [...]
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
27/04/2026
SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
27/04/2026
-- Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease -- DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton [...]
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
27/04/2026
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6- [...]
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
27/04/2026
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily pretreated PTCL population Responses highest in angioimmunoblastic T-cell [...]
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
27/04/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 12, 2026 NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
27/04/2026
CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
27/04/2026
Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and VANCOUVER, British Columbia, [...]
Composition of the Nomination Committee of Orion Corporation
27/04/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 APRIL 2026 at 12:00 EEST Composition of the Nomination Committee of Orion Corporation The Board of [...]

Pages